EVO101

DRUG2 trials

Sponsors

Evommune, Inc., Virginia Clinical Research, Inc.

Conditions

Atopic Dermatitis EczemaHidradenitis Suppurativa (HS)

Early Phase 1

Participants with Mild to Moderate Hidradenitis Suppurativa Will Receive EVO101 a Topical Cream 0.1%

RecruitingNCT06645821

Virginia Clinical Research, Inc.Hidradenitis Suppurativa (HS)

Start: 2024-12-03End: 2025-05-31Target: 15Updated: 2024-12-11

Phase 2

Safety and Efficacy Study of EVO101 Topical Cream in Atopic Dermatitis

CompletedNCT05579899

Evommune, Inc.Atopic Dermatitis Eczema

Start: 2022-09-27End: 2023-07-27Updated: 2025-03-05